Weiwei Hu

发表

A study on platinum(iv) species containing an estrogen receptor modulator to reverse tamoxifen resistance of breast cancer.

S. Gou, Jian Zhao, Weiwei Hu, 2018, Metallomics : integrated biometal science.

A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response.

S. Gou, Feihong Chen, Xiao-chao Huang, 2017, Cancer letters.

Combination of 7-hydroxycoumarin in a platinum(IV) complex derived from cisplatin enhanced cytotoxicity with multiple mechanisms of action.

S. Gou, Jian Zhao, Weiwei Hu, 2018, Journal of inorganic biochemistry.

Synthesis and biological evaluation of novel millepachine derivative containing aminophosphonate ester species as novel anti-tubulin agents.

Chungu Wang, T. Ma, Hengshan Wang, 2019, Bioorganic chemistry.

Synthesis and biological evaluation of water-soluble trans-[bicyclo[2.2.2]octane-7R,8R-diamine]platinum(II) complexes with linear or branched alkoxyacetates as leaving groups

S. Gou, Lei Fang, Weiwei Hu, 2016 .

Effect of chronic stress on tumorigenesis and development

Jiaping Ni, Yumeng Shen, Yong Yang, 2022, Cellular and Molecular Life Sciences.

Synthesis, characterization and biological evaluation of two cyclometalated iridium(III) complexes containing a glutathione S-transferase inhibitor.

Wei Wang, Weiyu He, Jian Zhao, 2022, Journal of inorganic biochemistry.

Differentiation therapy: Unlocking phenotypic plasticity of hepatocellular carcinoma.

Yumeng Shen, Yong Yang, Weiwei Hu, 2022, Critical reviews in oncology/hematology.

Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1.

S. Gou, Weiwei Hu, Zhimei Wang, 2017, European journal of medicinal chemistry.

Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance.

Chungu Wang, S. Gou, Hengshan Wang, 2019, Bioorganic chemistry.

CircPTK2 (hsa_circ_0005273) as a novel therapeutic target for metastatic colorectal cancer

R. Chen, Qingtao Meng, Shenshen Wu, 2020, Molecular Cancer.

PLAGL2‐EGFR‐HIF‐1/2α Signaling Loop Promotes HCC Progression and Erlotinib Insensitivity

L. Birnbaumer, Jiaping Ni, Jun-jie Yu, 2020, Hepatology.

CircPTK2 (hsa_circ_0005273) as a novel therapeutic target for metastatic colorectal cancer

R. Chen, Qingtao Meng, Shenshen Wu, 2020, Molecular Cancer.

Biotin-Pt (IV)-indomethacin hybrid: A targeting anticancer prodrug providing enhanced cancer cellular uptake and reversing cisplatin resistance.

S. Gou, Lei Fang, Weiwei Hu, 2017, Journal of inorganic biochemistry.

Effective platinum(IV) prodrugs conjugated with lonidamine as a functional group working on the mitochondria.

S. Gou, Hong Chen, Feihong Chen, 2018, Journal of inorganic biochemistry.

Novel Indole-Chalcone Derivative-Ligated Platinum(IV) Prodrugs Attenuate Cisplatin Resistance in Lung Cancer through ROS/ER Stress and Mitochondrial Dysfunction.

Ri-zhen Huang, Zhikun Liu, Xiao-chao Huang, 2023, Journal of medicinal chemistry.

2-Methoxyestradiol synergizes with Erlotinib to suppress hepatocellular carcinoma by disrupting the PLAGL2-EGFR-HIF-1/2α signaling loop.

Jiaping Ni, Ying Li, Haoying Zhang, 2021, Pharmacological research.

Effective platinum(IV) prodrugs conjugated with lonidamine as a functional group working on the mitochondria.

S. Gou, Hong Chen, Feihong Chen, 2018, Journal of inorganic biochemistry.